Integra LifeSciences Holdings
$ 10.57
2.42%
24 Apr - close price
- Market Cap 823,796,000 USD
- Current Price $ 10.57
- High / Low $ 10.57 / 10.03
- Stock P/E N/A
- Book Value 13.40
- EPS -6.74
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.40 %
- 52 Week High 17.54
- 52 Week Low 8.70
About
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
Analyst Target Price
$15.43
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-10-30 | 2025-07-31 | 2025-05-05 | 2025-02-26 | 2024-11-04 | 2024-07-29 | 2024-05-06 | 2024-02-28 | 2023-10-25 | 2023-07-26 | 2023-04-26 |
| Reported EPS | 0.83 | 0.54 | 0.45 | -0.3308 | 0.97 | 0.41 | 0.63 | 0.55 | 0.89 | 0.76 | 0.71 | 0.74 |
| Estimated EPS | 0.8002 | 0.43 | 0.44 | 0.4311 | 0.8554 | 0.39 | 0.62 | 0.55 | 0.9 | 0.78 | 0.57 | 0.74 |
| Surprise | 0.0298 | 0.11 | 0.01 | -0.7619 | 0.1146 | 0.02 | 0.01 | 0 | -0.01 | -0.02 | 0.14 | 0 |
| Surprise Percentage | 3.7241% | 25.5814% | 2.2727% | -176.7339% | 13.3972% | 5.1282% | 1.6129% | 0% | -1.1111% | -2.5641% | 24.5614% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.41 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $6.37 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IART
2026-04-21 11:39:41
Kaskela Law Firm has initiated an investigation into Integra LifeSciences Holdings Corp. (NASDAQ: IART) concerning potential breaches of fiduciary duty claims on behalf of long-term shareholders. This investigation follows a securities fraud complaint alleging that Integra issued false and misleading statements regarding its compliance with Good Manufacturing Practices. The complaint states that investors learned the full truth about Integra's "systematic, serious, and recurring" violations and shipping holds in July 2022, leading to a 21% stock price decline.
2026-04-21 08:08:51
Integra LifeSciences (NASDAQ: IART) will release its first-quarter 2026 financial results on Tuesday, May 5, 2026, before market open. Management will host a conference call at 8:30 a.m. ET, with a live webcast available on the company's investor website. Historical data suggests that similar earnings call announcements have typically led to mild negative stock movements, with an average change of -2.36%.
2026-04-16 06:09:58
Argus Research has downgraded Integra LifeSciences Holdings (IART). The article is a stub and provides no further details on the reasons for the downgrade or any financial implications.
2026-04-15 20:39:38
Integra LifeSciences Holdings Corporation has extended its $150 million accounts receivable securitization facility until April 10, 2029. This extension, achieved through amendments to the Receivables Financing Agreement and Purchase and Sale Agreement, ensures the company maintains access to diversified funding for ongoing liquidity and working capital needs. The amendments also adjust certain representations, covenants, and concentration limits related to the receivables backing the facility.
2026-04-15 15:38:57
Integra LifeSciences (NASDAQ:IART) shares gapped down following a price target cut from Truist Financial. Several other analysts have also lowered their ratings or price targets for the company, contributing to a "Reduce" average rating and a consensus target price of $14.20. Despite slightly beating Q4 EPS and revenue expectations, the company reported a negative net margin and offered conservative FY2026 EPS guidance.
2026-04-07 08:30:00
Integra LifeSciences will present new real-world data on its PriMatrix Dermal Scaffold at three major medical conferences in April, including analyses from nearly 1,000 cases across various wound types and a case series on burn injuries. The company emphasizes the product's role in complex reconstruction and limb salvage, adding to a growing body of evidence for its wound reconstruction portfolio. These presentations reinforce Integra's commitment to evidence-based solutions in advanced wound care.
